Vemurafenib in Patients With BRAF V600E Mutation-Positive Advanced Melanoma

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1474-1486

  Ravnan, Marcus C ^a   Matalka, Mazen S ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b ClinServ International Group Jordan   (Jordan)

Author keywords

BRAF; Malignant melanoma; PLX4032; Vemurafenib

Indexed keywords

B RAF KINASE; DACARBAZINE; GLUTAMIC ACID; IPILIMUMAB; MYDRIATIC AGENT; STEROID; VALINE; VEMURAFENIB;

ADVANCED CANCER; ALOPECIA; ARTHRALGIA; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIARRHEA; DIPLOPIA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENE MUTATION; HAZARD RATIO; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; MEDICAL RECORD REVIEW; MEDLINE; MELANOMA; MORTALITY; NAUSEA; ORBIT EDEMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RETINA VEIN OCCLUSION; REVIEW; SKIN ALLERGY; SKIN CARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH; UVEITIS;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84863814724     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.009     Document Type: Review

References (75)

1. National Cancer Institute Surveillance, Epidemiology And End Results (SEER) Program Accessed March 13, 2012. http://seer.cancer.gov/statfacts/html/melan.html.
2. American Society of Clinical Oncology Melanoma, Accessed March 1, 2012. http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/melanoma-skin-cancer-key-statistics.
3. American Cancer Society Melanoma Skin Cancer, Accessed March 10, 2012. http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/melanoma-skin-cancer-key-statistics.
4. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60:277-300.
5. Boyle G.M. Therapy for metastatic melanoma: An overview and update. Exp Rev Anticancer Ther 2011, 11:725-737.
6. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Melanoma version 3.2012 Accessed February 7, 2012. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf.
7. Eggermont A.M. Advances in systemic treatment of melanoma. Ann Oncol 2010, 21(Suppl 7):vii339-vii344.
8. Livingstone E., Zimmer L., Piel S., Schadendorf D. PLX4032: Does it keep its promise for metastatic melanoma treatment?. Exp Opin Investig Drugs 2010, 19:1439-1449.
9. Puzanov I., Flaherty K.T. Targeted molecular therapy in melanoma. Semin Cutan Med Surg 2010, 29:196-201.
10. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
11. Yang A.S., Chapman P.B. The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am 2009, 23:583-597.
12. Atkins M.B., Hsu J., Lee S., et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern cooperative oncology group. J Clin Oncol 2008, 26:5748-5754.
13. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
14. McDermott D.F., Atkins M.B. More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma. J Clin Oncol 2007, 25:3791-3793.
15. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
16. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
17. Fisher R., Cahalin P., Gore M., Larkin J. A tale of two tumours and a plea for progress. Lancet Oncol 2012, 13:124-125.
18. Sondak V.K., Smalley K.S., Kudchadkar R., et al. Ipilimumab. Nat Rev Drug Discov 2011, 10:411-412.
19. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
20. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
21. Gartside M.G., Chen H., Ibrahimi O.A., et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 2009, 7:41-54.
22. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
23. Flaherty K.T. BRAF inhibitors and melanoma. Cancer J 2011, 17:505-511.
24. Bollag G., Hirth P., Tsai J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
25. Ribas A., Flaherty K.T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011, 8:426-433.
26. FDA approves vemurafenib for treatment of metastatic melanoma. Oncology (Huntington, NY) 2011, 25:906.
27. Zelboraf (vemurafenib) [package insert], Accessed February 21, 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
28. Vemurafenib (zelboraf) for metastatic melanoma. Med Lett Drugs Ther 2011, 53:77-78.
29. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
30. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
31. Sosman J.A. BRAF inhibitor gives striking survival advantage in BRIM-3: commentary. Oncol Rep 2011, 29.
32. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
33. Joseph E.W., Pratilas C.A., Poulikakos P.I., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010, 107:14903-14908.
34. Lee J.T., Li L., Brafford P.A., et al. PLX4032, a potent inhibitor of the B-raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010, 23:820-827.
35. Halaban R., Zhang W., Bacchiocchi A., et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23:190-200.
36. FDA Center for Drug Evaluation and Research summary application review, Accessed March 1, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429Orig1s000SumR.pdf.
37. FDA Center for Drug Evaluation and Research chemistry review, Accessed March 1, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000ChemR.pdf.
38. FDA Center for Drug Evaluation and Research, clinical pharmacology and biopharmaceutics review(s), Accessed March 1, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000ClinPharmR.pdf.
39. White R.M. The natural history of malignancies under conditions of BRAF inhibitor stimulation. Expert Opin Investig Drugs 2011, 20:135-136.
40. Nazarian R., Shi H., Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
41. Su F., Bradley W.D., Wang Q., et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012, 72:969-978.
42. Wellbrock C., Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010, 80:561-567.
43. Tsao H., Goel V., Wu H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004, 122:337-341.
44. Albino A.P., Fountain J.W. Molecular genetics of human malignant melanoma. Cancer Treat Res 1993, 65:201-255.
45. Sosman J.A., Margolin K.A. Inside life of melanoma cell signaling, molecular insights, and therapeutic targets. Curr Oncol Rep 2009, 11:405-411.
46. Satyamoorthy K., Li G., Gerrero M.R., et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003, 63:756-759.
47. Solit D., Rosen N. Oncogenic RAF: A brief history of time. Pigment Cell Melanoma Res 2010, 23:760-762.
48. Lee J.T., Herlyn M. MEK'ing the most of p53 reactivation therapy in melanoma. J Invest Dermatol 2012, 132:263-265.
49. Guldberg P., thor Straten P., Birck A., et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997, 57:3660-3663.
50. Birck A., Ahrenkiel V., Zeuthen J., et al. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 2000, 114:277-280.
51. Flaherty K.T., Yasothan U., Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011, 10:811-812.
52. Heakal Y., Kester M., Savage S. Vemurafenib (PLX4032): An orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother 2011, 45:1399-1405.
53. FDA Medical Device Approval Cobas 4800 BRAF V600 Mutation Test Accessed March 1, 2012. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm268836.htm.
54. Ribas A., Kim K.B., Schuchter L.M., et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011, 29(suppl). Abstract 8509.
55. Clinical trials, BRIM-3 results Accessed March 5, 2012. http://clinicaltrials.gov/ct2/show/results/NCT01006980?term=vemurafenib%26rank=4.
56. Dummer R., Rinderknecht J., Goldinger S.M. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012, 366:480-481.
57. Lemech C., Arkenau H. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights: Oncology 2012, 6:53-66.
58. Oberholzer P.A., Kee D., Dziunycz P., et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012, 30:316-321.
59. Su F., Viros A., Milagre C., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366:207-215.
60. Lacouture M.E., O'Reilly K., Rosen N., Solit D.B. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: Cause for concern?. J Clin Oncol 2012, 30:329-330.
61. Koneru M., Carvajal R.D. A new era for the management of metastatic melanoma. Exp Rev Dermatol 2012, 7:27-35.
62. Harding J.J., Pulitzer M., Chapman P.B. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med 2012, 366:866-868.
63. Chapman P.B., Hauschild A., McArthur G.A. The authors reply. N Engl J Med 2011, 365:1450.
64. Poulikakos P.I., Persaud Y., Janakiraman M., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
65. Goydos J.S., Mann B., Kim H.J., et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005, 200:362-370.
66. Fedorenko I.V., Paraiso K.H.T., Smalley K.S.M. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 2011, 82:201-209.
67. Shi H., Kong X., Ribas A., Lo R.S. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011, 71:5067-5074.
68. Solit D.B., Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011, 364:772-774.
69. Johannessen C.M., Boehm J.S., Kim S.Y., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
70. Paraiso K.H., Xiang Y., Rebecca V.W., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71:2750-2760.
71. Kaplan F.M., Mastrangelo M.J., Aplin A.E. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. J Invest Dermatol 2010, 130:2669-2671.
72. Kaplan F.M., Shao Y., Mayberry M.M., Aplin A.E. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 2011, 30:366-371.
73. Lo R.S. Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas. Pharmacogenomics 2012, 13:125-128.
74. Greger J., Eastman S., Zhang V., et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012, 11:909-920.
75. Kudchadkar R., Paraiso K.H., Smalley K.S. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 2012, 18:124-131.